Sugi Predict

Sugi Predict / Compounds / SCHEMBL412579

SCHEMBL412579

SCHEMBL412579

COc1cccc(CNc2ccc3nc(-c4ccccc4F)nc(Nc4ccncc4)c3c2)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 9/20 0.53
▸ KMT2A Q03164 9/20 0.53
▸ MAPT P10636 6/20 0.53
▸ LMNA P02545 6/20 0.53
▸ MAPK1 P28482 5/20 0.53
▸ CYP1A2 P05177 5/20 0.53
▸ CYP3A4 P08684 5/20 0.53
▸ CYP2D6 P10635 4/20 0.53
▸ CYP2C19 P33261 4/20 0.53
▸ TP53 P04637 2/20 0.53
▸ KDM4E B2RXH2 1/20 0.53
▸ HPGD P15428 1/20 0.53
▸ CASP1 P29466 1/20 0.53
▸ CASP7 P55210 1/20 0.53
▸ SMN1; SMN2 Q16637 1/20 0.53
▸ CLK4 Q9HAZ1 4/20 0.51
▸ USP2 O75604 3/20 0.51
▸ ALDH1A1 P00352 3/20 0.51
▸ HSD17B10 Q99714 3/20 0.51
▸ ALOX15 P16050 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL409822 0.91 MEN1 (0.52) MEN1KMT2AMAPTLMNAMAPK1
Ammonia Solution, Strong SCHEMBL3488927 0.88 MEN1 (0.55) MEN1KMT2AMAPTLMNAMAPK1
SCHEMBL408415 0.82 MAPT (0.48) MEN1KMT2AMAPTLMNAMAPK1
SCHEMBL1058063 0.80 MEN1 (0.52) MEN1KMT2AMAPTLMNAMAPK1
SCHEMBL14262814 0.78 ABCG2 (0.53) MEN1KMT2AMAPTLMNAMAPK1
SCHEMBL4082133 0.77 MEN1 (0.55) MEN1KMT2AMAPTLMNAMAPK1
SCHEMBL4092472 0.76 LMNA (0.67) MEN1KMT2AMAPTLMNAMAPK1
SCHEMBL14262819 0.76 MEN1 (0.53) MEN1KMT2AMAPTLMNAMAPK1
SCHEMBL14262904 0.75 MEN1 (0.76) MEN1KMT2AMAPTLMNAMAPK1
SCHEMBL1063104 0.75 MEN1 (0.57) MEN1KMT2AMAPTLMNAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1107959-B1 QUINAZOLINE DERIVATIVES AS MEDICAMENTS SCIOS INC (US) 2006-10-11 — — EP claimed
US-20050171123-A1 Quinazoline derivatives as medicaments SCIOS, INC. 2005-08-04 — — US claimed
US-6903096-B2 Quinazoline derivatives as medicaments SCIOS, INC. (US) 2005-06-07 — — US claimed
CN-1152867-C Quinazoline derivatives as medicaments �����ɷ� 2004-06-09 — — CN claimed
US-20030069248-A1 Quinazoline derivatives as medicaments CHAKRAVARTY SARVAJIT (US) 2003-04-10 — — US claimed
US-6476031-B1 Quinazoline derivatives as medicaments SCIOS, INC. 2002-11-05 — — US claimed
US-20020161010-A1 Quinazoline derivatives as medicaments CHAKRAVARTY SARVAJIT (US) 2002-10-31 — — US claimed
JP-2002523502-A — — 2002-07-30 — — JP claimed
CN-1333757-A Quinazoline derivatives as medicaments SCIOS INC (US) 2002-01-30 — — CN claimed
US-6277989-B1 USEFUL IN TREATING CONDITIONS THAT ARE CHARACTERIZED BY ENHANCED P38 KINASE ACTIVITY AND/OR TRANSFORMING GROWTH FACTOR BETA (TGF-.BETA.) ACTIVITY SUCH AS INFLAMMATION, PROLIFERATIVE DISEASES, AND CERTAIN CARDIOVASCULAR DISORDERS SCIOS, INC. 2001-08-21 — — US claimed
EP-1107959-A2 QUINAZOLINE DERIVATIVES AS MEDICAMENTS SCIOS INC. (US) 2001-06-20 — — EP claimed
US-6184226-B1 ANTIINFLAMMATORY AGENTS FOR TREATMENT OF CARDIOVASCULAR SYSTEM DISORDERS/RESPIRATORY SYSTEM DISORDERS, ANTIISCHEMIC AGENTS SCIOS INC. 2001-02-06 — — US claimed
WO-2000012497-A2 QUINAZOLINE DERIVATIVES AS MEDICAMENTS SCIOS INC. (US) 2000-03-09 — — WO claimed
US-20140120621-A1 TGF-BETA RECEPTOR INHIBITORS TO ENHANCE DIRECT REPROGRAMMING THE GENERAL HOSPITAL CORPORATION (US) 2014-05-01 — — US disclosed
US-8603818-B1 TGF-beta receptor inhibitors to enhance direct reprogramming THE GENERAL HOSPITAL CORPORATION (US) 2013-12-10 — — US disclosed
US-8298825-B1 TGF-beta receptor inhibitors to enhance direct reprogramming THE GENERAL HOSPITAL CORPORATION (US) 2012-10-30 — — US disclosed
WO-2004004725-A2 PHARMACEUTICAL COMPOSITIONS OF ANTICHOLINERGICS AND P38 KINASE INHIBITORS IN THE TREATMENT OF RESPIRATORY DISEASES BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2004-01-15 — — WO disclosed
US-20030225089-A1 Pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2003-12-04 — — US disclosed
US-20030220336-A1 Method of treating mucus hypersecretion BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2003-11-27 — — US disclosed
WO-2003084503-A2 P38 KINASE INHIBITORS FOR TREATING MUCUS HYPERSECRETION_ BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2003-10-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020161010-A1 Quinazoline derivatives as medicaments SMAD3, SMAD2, TGFBR1 MEN1 1621/4885KMT2A 2523/4885MAPT 4399/4885
US-20030225089-A1 Pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors CHRM3, CHRM2, CHRNB1 MEN1 4779/4885KMT2A 3165/4885MAPT 623/4885
US-20050171123-A1 Quinazoline derivatives as medicaments TGFBR2, SMAD2, ADRB2 MEN1 1936/4885KMT2A 1871/4885MAPT 4024/4885
US-20030069248-A1 Quinazoline derivatives as medicaments SMAD3, SMAD2, TGFBR1 MEN1 1621/4885KMT2A 2523/4885MAPT 4399/4885
US-20030220336-A1 Method of treating mucus hypersecretion MUC1, CFTR, MAPKAPK5 MEN1 4080/4885KMT2A 4014/4885MAPT 3069/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.